Insmed to Participate at November Investor Conferences

BRIDGEWATER, N.J., Nov. 14, 2016 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the following investor conferences taking place in New York City:

• Will Lewis, president and chief executive officer, will participate in an analyst-led fireside chat on Wednesday, November 16 at 10:15 AM ET at the Stifel Healthcare Conference. 
• Mr. Lewis will also participate in an analyst-led fireside chat on Tuesday, November 29 at 7:30 AM ET at the Piper Jaffray Healthcare Conference.

The presentations will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral inhibitor of dipeptidyl peptidase I with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled prodrug formulation of treprostinil that may offer a differentiated product profile for rare pulmonary disorders. For more information, visit www.insmed.com.

“Insmed” and “ARIKAYCE” are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.

Insmed Incorporated:

Susan Mesco
Head of Investor Relations
908-947-4326